Cogent Biosciences, Inc.
COGT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001622229
In the last 90 days, Cogent Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 322 institutions reported holding it in 13F filings for Q2 2026, worth $7.50B in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Cogent Biosciences, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 149 | 1 | 161 | +13 |
| Shares | 121.4M | 7.29M | 121.8M | +7.72M (+6.8%) |
| Value | $1.02B | $61.4M | $1.32B | +$354.3M (+36.8%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (32)
Institutions that held Cogent Biosciences, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (19)
Institutions that held Cogent Biosciences, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Readystate Asset Management LP | 734,197 | $6.19M |
| Deep Track Capital, LP | 308,235 | $2.60M |
| American Century Companies Inc | 44,997 | $379.3K |
| Tudor Investment Corp Et Al | 42,532 | $358.5K |
| Jump Financial, LLC | 37,695 | $317.8K |
| EntryPoint Capital, LLC | 25,137 | $211.9K |
| Atom Investors LP | 23,174 | $195.4K |
| Graham Capital Management, L.P. | 23,101 | $194.7K |
| Brevan Howard Capital Management LP | 22,559 | $190.2K |
| Schroder Investment Management Group | 16,598 | $139.9K |
| Principal Financial Group Inc | 16,211 | $136.7K |
| Laurion Capital Management LP | 13,612 | $114.7K |
| Corton Capital Inc. | 12,162 | $102.5K |
| Colony Group, LLC | 11,628 | $98.0K |
| E Fund Management Co., Ltd. | 11,173 | $94.2K |
| Entropy Technologies, LP | 10,638 | $89.7K |
| Pacer Advisors, Inc. | 1,046 | $8.82K |
| US Bancorp | 137 | $1.16K |
| Innealta Capital, LLC | 86 | $725 |
Not filed for Q3 2024 yet (1)
Institutions that held Cogent Biosciences, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 7,288,378 | $61.4M |